Switzerland-based DKSH Management Ltd. has entered a distribution partnership with BridgeBio Pharma (Nasdaq: BBIO) to support regulatory filings and, subject to approval, commercialization of acoramidis (Attruby/Beyonttra) for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in Australia, Singapore, South Korea, and Taiwan. The arrangement covers an oral small molecule that has already secured approvals in the US, EU, UK, Japan, Switzerland, and Brazil, but remains unapproved across the four covered markets. Financial terms were not disclosed.
Acoramidis is a selective oral TTR stabilizer described by BridgeBio as achieving near-complete (≥90%) stabilization of the transthyretin tetramer, a mechanism that prevents the protein from misfolding and depositing as amyloid in the heart. The drug is approved for adults with wild-type or variant ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
The Phase III ATTRibute-CM study underpins the approvals secured to date. Long-term open-label extension data published in March 2026 showed a statistically significant 44.7% reduction in all-cause mortality and 49.3% reduction in cardiovascular mortality at Month 54 versus patients who had received placebo before crossing over.
Under the deal, DKSH will handle regulatory affairs, medical affairs, market access, and distribution across the four territories. BridgeBio reported Q1 2026 US net product revenue of USD 180.6 million for Attruby, with Bayer serving as its exclusive European licensing partner.